Terms: = Breast cancer AND FES, FPS, 2242, ENSG00000182511, P07332 AND Treatment
97 results:
1. Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD.
Chen M; Zhang X; Ming Z; Lingyu ; Feng X; Han Z; An HX
J Transl Med; 2024 Mar; 22(1):315. PubMed ID: 38539235
[TBL] [Abstract] [Full Text] [Related]
2. Can 18F-fes PET Improve the Evaluation of 18F-FDG PET in Patients With Metastatic Invasive Lobular Carcinoma?
Liu C; Ma G; Xu X; Song S; Yang Z
Clin Nucl Med; 2024 Apr; 49(4):301-307. PubMed ID: 38427956
[TBL] [Abstract] [Full Text] [Related]
3. Women's Health Update: Growing Role of PET for Patients with breast cancer.
Ulaner GA; Vaz SC
Semin Nucl Med; 2024 Mar; 54(2):247-255. PubMed ID: 38365547
[TBL] [Abstract] [Full Text] [Related]
4. The Current and Future Roles of Precision Oncology in Advanced breast cancer.
Jacene H; Dietsche E; Specht J
J Nucl Med; 2024 Mar; 65(3):349-356. PubMed ID: 38302151
[TBL] [Abstract] [Full Text] [Related]
5. Quarter-Century Transformation of Oncology: Positron Emission Tomography for Patients with breast cancer.
Ulaner GA; Vaz SC; Groheux D
PET Clin; 2024 Apr; 19(2):147-162. PubMed ID: 38177052
[TBL] [Abstract] [Full Text] [Related]
6. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with breast cancer Using 16α-[
Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
[TBL] [Abstract] [Full Text] [Related]
7.
Liu C; Ma G; Zhang J; Cheng J; Yang Z; Song S
Ann Nucl Med; 2023 Dec; 37(12):675-684. PubMed ID: 37787851
[TBL] [Abstract] [Full Text] [Related]
8. Diffuse bilateral
Phillips EF; Karak PK
J Med Imaging Radiat Sci; 2023 Dec; 54(4):726-731. PubMed ID: 37620179
[TBL] [Abstract] [Full Text] [Related]
9. The Application of 18 F-fes PET in Clinical cancer Care : A Systematic Review.
Huang YT; Chen TW; Chen LY; Huang YY; Lu YS
Clin Nucl Med; 2023 Sep; 48(9):785-795. PubMed ID: 37482660
[TBL] [Abstract] [Full Text] [Related]
10. An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor-Positive breast cancer.
Chandarlapaty S; Dickler MN; Perez Fidalgo JA; Villanueva-Vázquez R; Giltnane J; Gates M; Chang CW; Cheeti S; Fredrickson J; Wang X; Collier A; Moore HM; Metcalfe C; Lauchle J; Humke EW; Bardia A
Clin Cancer Res; 2023 Aug; 29(15):2781-2790. PubMed ID: 37261814
[TBL] [Abstract] [Full Text] [Related]
11. Homologous recombination deficiency status predicts response to platinum-based chemotherapy in Chinese patients with high-grade serous ovarian carcinoma.
Feng Z; Shao D; Cai Y; Bi R; Ju X; Chen D; Song C; Chen X; Li J; An N; Li Y; Zhou Q; Xiu Z; Zhu S; Wu X; Wen H
J Ovarian Res; 2023 Mar; 16(1):53. PubMed ID: 36922847
[TBL] [Abstract] [Full Text] [Related]
12.
O'Brien SR; Edmonds CE; Lanzo SM; Weeks JK; Mankoff DA; Pantel AR
Radiographics; 2023 Mar; 43(3):e220143. PubMed ID: 36821506
[TBL] [Abstract] [Full Text] [Related]
13. The Role of Theragnostics in breast cancer: A Systematic Review of the Last 12 Years.
Balma M; Liberini V; Buschiazzo A; Racca M; Rizzo A; Nicolotti DG; Laudicella R; Quartuccio N; Longo M; Perlo G; Terreno E; Abgral R; William Huellner M; Papaleo A; Deandreis D
Curr Med Imaging; 2023; 19(8):817-831. PubMed ID: 36797602
[TBL] [Abstract] [Full Text] [Related]
14. [18F]FDG and [18F]fes PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ breast cancer Undergoing treatment with Rintodestrant.
Iqbal R; Yaqub M; Bektas HO; Oprea-Lager DE; de Vries EGE; Glaudemans AWJM; Aftimos P; Gebhart G; Beelen AP; Schuit RC; Windhorst AD; Boellaard R; Menke-van der Houven van Oordt CW
Clin Cancer Res; 2023 Jun; 29(11):2075-2084. PubMed ID: 36735488
[TBL] [Abstract] [Full Text] [Related]
15. The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 -) advanced/metastatic breast cancer.
Bardia A; Mayer I; Winer E; Linden HM; Ma CX; Parker BA; Bellet M; Arteaga CL; Cheeti S; Gates M; Chang CW; Fredrickson J; Spoerke JM; Moore HM; Giltnane J; Friedman LS; Chow Maneval E; Chan I; Jhaveri K
Breast Cancer Res Treat; 2023 Jan; 197(2):319-331. PubMed ID: 36401732
[TBL] [Abstract] [Full Text] [Related]
16. Molecular Imaging for Estrogen Receptor-Positive breast cancer: Clinical Applications of Whole Body and Dedicated breast Positron Emission Tomography.
Goodman K; Abel MK; Lawhn-Heath C; Molina-Vega J; Jones EF; Mukhtar RA
Surg Oncol Clin N Am; 2022 Oct; 31(4):569-579. PubMed ID: 36243494
[No Abstract] [Full Text] [Related]
17. Evaluation of tumour heterogeneity by
Liu C; Hu S; Xu X; Zhang Y; Wang B; Song S; Yang Z
Breast Cancer Res; 2022 Aug; 24(1):57. PubMed ID: 36028895
[TBL] [Abstract] [Full Text] [Related]
18. PET Imaging of Estrogen Receptors for Gynecological Tumors.
Tsujikawa T; Makino A; Mori T; Tsuyoshi H; Kiyono Y; Yoshida Y; Okazawa H
Clin Nucl Med; 2022 Jul; 47(7):e481-e488. PubMed ID: 35675139
[TBL] [Abstract] [Full Text] [Related]
19. 18F-fes PET/CT Improves the Detection of Intraorbital Metastases in Estrogen-Receptor-Positive breast cancer: Two Representative Cases and Review of the Literature.
Bodapati S; Abraham P; Chen A; Guilbault D; McDonald M; Matro J; Shatsky R; Obrzut S
Tomography; 2022 Apr; 8(2):1060-1065. PubMed ID: 35448720
[TBL] [Abstract] [Full Text] [Related]
20. 16α-18F-fluoro-17β-Fluoroestradiol (fes): Clinical Applications for Patients With breast cancer.
Ulaner GA
Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
[TBL] [Abstract] [Full Text] [Related]
[Next]
